Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 179, Issue 1, 2009, Pages 41-47

  Van Hees, Hieronymus W H ^a   Dekhuijzen, P N Richard ^a   Heunks, Leo M A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Calcium sensitization; Chronic obstructive pulmonary disease; Diaphragm; Levosimendan

Indexed keywords

CALCIUM SENSITIZER; LEVOSIMENDAN; MYOSIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; BREATHING MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; MALE; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE CONTRACTILITY; MUSCLE FORCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORACOTOMY;

AGED; CARDIOTONIC AGENTS; COMORBIDITY; DIAPHRAGM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDRAZONES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE PROTEINS; MYOSIN HEAVY CHAINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRIDAZINES;

EID: 58349096259     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200805-732OC     Document Type: Article

References (40)

1. Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med 2003;168:10-48.
2. Ottenheijm CA, Heunks LM, Dekhuijzen PN. Diaphragm muscle fiber dysfunction in chronic obstructive pulmonary disease: toward a pathophysiological concept. Am J Respir Crit Care Med 2007;175:1233-1240.
3. Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:961-966.
4. Nava S, Rubini F, Zanotti E, Ambrosino N, Bruschi C, Vitacca M, Fracchia C, Rampulla C. Survival and prediction of successful ventilator weaning in COPD patients requiring mechanical ventilation for more than 21 days. Eur Respir J 1994;7:1645-1652.
5. Ottenheijm CA, Heunks LM, Sieck GC, Zhan WZ, Jansen SM, Degens H. de BT, Dekhuijzen PN. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:200-205.
6. Ottenheijm CA, Heunks LM, Hafmans T, van der Ven PF, Benoist C, Zhou H, Labeit S, Granzier HL, Dekhuijzen PN. Titin and diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:527-534.
7. Ottenheijm CA, Heunks LM, Li YP, Jin B, Minnaard R, van Hees HW, Dekhuijzen PN. Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:997-1002.
8. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995;25:794-801.
9. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
10. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-113.
11. Sorsa T, Pollesello P, Permi P, Drakenberg T, Kilpelainen I. Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. J Mol Cell Cardiol 2003;35:1055-1061.
12. Levine S, Kaiser L, Leferovich J, Tikunov B. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med 1997;337:1799-1806.
13. van Hees HW, van der Heijden HF, Ottenheijm CA, Heunks LM, Pigmans CJ, Verheugt FW, Brouwer RM, Dekhuijzen PN. Diaphragm single-fiber weakness and loss of myosin in congestive heart failure rats. Am J Physiol Heart Circ Physiol 2007;293:819-828.
14. Zuurbier CJ, Heslinga JW, Lee-de Groot MB, van der Laarse WJ. Mean sarcomere length-force relationship of rat muscle fibre bundles. J Biomech 1995;28:83-87.
15. Burkholder TJ, Lieber RL. Sarcomere length operating range of vertebrate muscles during movement. J Exp Biol 2001;204:1529-1536.
16. Brenner B. Technique for stabilizing the striation pattern in maximally calcium-activated skinned rabbit psoas fibers. Biophys J 1983;41:99-102.
17. Sweeney HL, Corteselli SA, Kushmerick MJ. Measurements on permeabilized skeletal muscle fibers during continuous activation. Am J Physiol 1987;252:C575-C580.
18. 2+-activated tension generation of skinned skeletal muscle fibers. J Gen Physiol 1975;66:427-444.
19. Geiger PC, Cody MJ, Sieck GC. Force-calcium relationship depends on myosin heavy chain and troponin isoforms in rat diaphragm muscle fibers. J Appl Physiol 1999;87:1894-1900.
20. Jubran A, Tobin MJ. Pathophysiologic basis of acute respiratory distress in patients who fail a trial of weaning from mechanical ventilation. Am J Respir Crit Care Med 1997;155:906-915.
21. Laghi F, Jubran A, Topeli A, Fahey PJ, Garrity ER Jr, Arcidi JM, de Pinto DJ, Edwards LC, Tobin MJ. Effect of lung volume reduction surgery on neuromechanical coupling of the diaphragm. Am J Respir Crit Care Med 1998;157:475-483.
22. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006;113:305-315.
23. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004;486:67-74.
24. 2+ cycling in skeletal muscle. J Muscle Res Cell Motil 2007;28:259-274.
25. De TA, Leeper JB, McKenzie DK, Gandevia SC. Neural drive to the diaphragm in patients with severe COPD. Am J Respir Crit Care Med 1997;155:1335-1340.
26. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin-C. Mol Cell Biochem 2004;266:87-107.
27. Roher A, Lieska N, Spitz W. The amino acid sequence of human cardiac troponin-C. Muscle Nerve 1986;9:73-77.
28. Dhoot GK, Perry SV. Distribution of polymorphic forms of troponin components and tropomyosin in skeletal muscle. Nature 1979;278:714-718.
29. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003;107:81-86.
30. Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. Clin Pharmacokinet 2007;46:535-552.
31. Vassilakopoulos T, Zakynthinos S, Roussos C. Respiratory muscles and weaning failure. Eur Respir J 1996;9:2383-2400.
32. Vassilakopoulos T, Zakynthinos S, Roussos C. The tension-time index and the frequency/tidal volume ratio are the major pathophysiologic determinants of weaning failure and success. Am J Respir Crit Care Med 1998;158:378-385.
33. Jubran A. Critical illness and mechanical ventilation: effects on the diaphragm. Respir Care 2006;51:1054-1061.
34. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, Foster E, Chatterjee K. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005;111:1504-1509.
35. Littleton SW, Laghi F, Sinderby C, Beck J, Tobin MJ, Jubran A. Can patients who fail a weaning trial develop short-lasting diaphragmatic fatigue? [abstract]. Am J Respir Crit Care Med 2008;177:A375.
36. Allen DG, Lamb GD, Westerblad H. Skeletal muscle fatigue: cellular mechanisms. Physiol Rev 2008;88:287-332.
37. Millar NC, Homsher E. The effect of phosphate and calcium on force generation in glycerinated rabbit skeletal muscle fibers: a steady-state and transient kinetic study. J Biol Chem 1990;265:20234-20240.
38. Levine S, Nguyen T, Taylor N, Friscia ME, Budak MT, Rothenberg P, Zhu J, Sachdeva R, Sonnad S, Kaiser LR, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med 2008;358:1327-1335.
39. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-1912.
40. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSIAN). Eur Heart J 2002;23:1422-1432.